In vitro diagnostic (IVD) testing has long been a silent champion of healthcare, directing over 60% of clinical decisionmaking, although it accounts for only 2% of global healthcare spending. Roche’s Diagnostics Division is the world’s leading supplier of in vitro diagnostics (IVDs).
We have four in vitro business areas such as Professional Diagnostics, Molecular Diagnostics, Tissue Diagnostics and Diabetes Care. The fifth business area is Applied Science which is a world-class supplier of speciality biochemicals and producer of research reagents and systems for Life Science research.
Roche Applied Science
Roche Applied Science (RAS) is a worldclass supplier of speciality biochemicals and producer of research reagents and systems for Life Science research. RAS is an established partner for research institutions, universities and pharmaceutical industry worldwide. Its products facilitate medical research in today’s most important avenues of exploration and provide tools for researching the cause of and predisposition for a disease. RAS products often represent the first entry into innovative bioanalytical tools and methods and have potential to one day be developed for use as an IVD. The global Life Science research market, valued at 8 billion US dollars, grew approximately 8% in 2010. Roche has roughly a 10% share of this market.
Roche Professional Diagnostics (RPD) is the largest Business Area. It is a leading supplier of solutions, instrument systems, tests, software and services that help laboratories deliver reliable results more efficiently and cost-effectively. It is also strengthening its position as a leader in
the growing market for point-of-care testing products to support clinical decision-making close to the patient, in doctors’ offices, emergency rooms and other primary and specialty care settings. Furthermore, RPD develops laboratory information, workflow and data management solutions as well as connectivity components to maximise laboratory efficiency.
Roche Molecular Diagnostics (RMD) develops and produces innovative tests based on the Nobel Prize-winning discovery of the polymerase chain reaction (PCR). The tests developed by this business area for oncology, virology, HPV, microbiology and for screening blood products are used around the world by researchers, doctors, patients, hospitals, laboratories and blood banks. A new generation of RMD tests supports healthcare providers in choosing medications based on molecular characteristics of diseases and in monitoring treatments. The systems developed by RMD for screening blood and blood products help ensure that these products are safe before they come into contact with patients.
Roche Tissue Diagnostics (RTD) / Ventana Medical Systems Inc. in North America is the world-leading supplier of tissue-based cancer diagnostics. It develops and manufactures medical diagnostic instruments and reagent systems that provide leading-edge automation technology for use in slide-based tissue diagnosis of cancer and infectious disease. In addition, the company offers premier work?ow solutions designed to improve laboratory work?ow efficiency, providing automated safeguards to enhance the quality of patient healthcare. Its instruments and reagent systems are used in histology, cytology and drug discovery laboratories worldwide.
Roche Diabetes Care (RDC) develops and commercialises blood glucose (bG) monitoring and insulin delivery systems, that enable people with diabetes to manage their condition more effectively. The goal of diabetes therapy is to maintain the bG levels in a (near-) normal range and thus avoid diabetes-related complications. RDC not only offers individual product innovations but integrated diabetes management solutions meeting the everyday needs of our customers for an optimised therapy management. Roche is the indurstry leader in the global bG monitoring market worth over 8 billion US dollars.
Diabetes is a condition in which the body does not produce or properly use the hormone insulin. Epidemiological evidence suggests that, without effective prevention and control programs, diabetes is likely to continue to increase globally. Estimates of the World Health Organization (WHO) and International Diabetes Federation (IDF) project a number of 380 million people having diabetes by the year 2025. This means an increase of 55% as of 2007.
Due to the complications arising from diabetes, it is set to be one of the most challenging health problems in the 21st century. Diabetes-related complications include
- Cardiovascular disease (e.g. coronary artery disease, stroke)
- Retinopathy (disease of the retina resulting in visual impairment and potentially leading to blindness)
- Neuropathy (disease of the nervous system), foot ulcers and lower limb amputation
- Kidney failure (diabetes is a leading cause of end-stage renal disease)
These complications result in increasing disability, reduced life expectancy and enormous healthcare costs for virtually every society. In most developed countries diabetes is the fourth leading cause of death.
Attached media for this topic
|Roche Diagnostics Business Overview 2013|
|Fact Sheet Diabetes|
|Roche Diabetes Care Fact Sheet|
|Backgrounder Diabetes epidemic proportions|
|Backgrounder Commitment Beyond Products|